Pfizer, Inc. (NYSE:PFE) – Stock analysts at Leerink Swann boosted their Q4 2016 EPS estimates for shares of Pfizer in a note issued to investors on Wednesday. Leerink Swann analyst S. Fernandez now anticipates that the firm will post earnings per share of $0.50 for the quarter, up from their prior estimate of $0.49. Leerink Swann also issued estimates for Pfizer’s FY2021 earnings at $2.94 EPS.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 1st. The biopharmaceutical company reported $0.61 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by $0.01. Pfizer had a net margin of 13.09% and a return on equity of 23.68%. The firm earned $13.05 billion during the quarter, compared to the consensus estimate of $13.05 billion. During the same period in the prior year, the company posted $0.60 EPS. The firm’s revenue was up 7.9% compared to the same quarter last year.
Several other brokerages also recently weighed in on PFE. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday. Sanford C. Bernstein set a $35.00 price target on Pfizer and gave the company a “buy” rating in a research note on Tuesday. Piper Jaffray Companies set a $53.00 price target on Pfizer and gave the company a “buy” rating in a research note on Saturday, January 21st. Jefferies Group LLC restated a “hold” rating and issued a $30.00 target price on shares of Pfizer in a research note on Thursday, January 19th. Finally, Vetr downgraded Pfizer from a “strong-buy” rating to a “buy” rating and set a $35.83 target price on the stock. in a research note on Wednesday, January 18th. Thirteen equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $37.07.
Pfizer (NYSE:PFE) traded up 0.591% on Friday, reaching $31.465. The company’s stock had a trading volume of 9,762,916 shares. The firm’s 50 day moving average price is $32.42 and its 200-day moving average price is $33.49. Pfizer has a 1-year low of $28.25 and a 1-year high of $37.39. The company has a market capitalization of $190.94 billion, a price-to-earnings ratio of 31.591 and a beta of 0.91.
A number of institutional investors have recently made changes to their positions in PFE. Nelson Roberts Investment Advisors LLC increased its position in shares of Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 189 shares in the last quarter. Tuttle Tactical Management LLC bought a new position in shares of Pfizer during the second quarter worth $117,000. First National Bank Sioux Falls increased its position in shares of Pfizer by 108.2% in the third quarter. First National Bank Sioux Falls now owns 3,367 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,750 shares in the last quarter. Cornerstone Advisors Inc. increased its position in shares of Pfizer by 17.4% in the third quarter. Cornerstone Advisors Inc. now owns 3,650 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 541 shares in the last quarter. Finally, Gierl Augustine Investment Management Inc increased its position in shares of Pfizer by 5.8% in the third quarter. Gierl Augustine Investment Management Inc now owns 3,718 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 205 shares in the last quarter. 69.51% of the stock is owned by hedge funds and other institutional investors.
In related news, insider Anthony J. Maddaluna sold 10,000 shares of Pfizer stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $33.00, for a total transaction of $330,000.00. Following the completion of the transaction, the insider now directly owns 112,087 shares of the company’s stock, valued at approximately $3,698,871. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Albert Bourla sold 18,390 shares of Pfizer stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $30.05, for a total transaction of $552,619.50. Following the transaction, the insider now directly owns 149,199 shares of the company’s stock, valued at $4,483,429.95. The disclosure for this sale can be found here. Company insiders own 0.07% of the company’s stock.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 1st. Investors of record on Friday, February 3rd will be issued a dividend of $0.32 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.30. This represents a $1.28 annualized dividend and a yield of 4.09%. The ex-dividend date of this dividend is Wednesday, February 1st. Pfizer’s dividend payout ratio (DPR) is currently 106.20%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company’s segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products.